{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:48:52Z","timestamp":1787683732320,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T00:00:00Z","timestamp":1567382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T00:00:00Z","timestamp":1567382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12874-019-0823-8","type":"journal-article","created":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T18:09:38Z","timestamp":1567447778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-9485","authenticated-orcid":false,"given":"Shannon","family":"Cope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Ayers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Batt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen P.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,2]]},"reference":[{"issue":"6","key":"823_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","volume":"33","author":"NR Latimer","year":"2013","unstructured":"Latimer NR. Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Mak. 2013;33(6):743\u201354.","journal-title":"Med Decis Mak"},{"issue":"4","key":"823_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/0272989X16639900","volume":"37","author":"C Jackson","year":"2017","unstructured":"Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A, Sharples L. Extrapolating survival from randomized trials using external data: a review of methods. Med Decis Mak. 2017;37(4):377\u201390.","journal-title":"Med Decis Mak"},{"key":"823_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12874-016-0186-3","volume":"16","author":"B Grigore","year":"2016","unstructured":"Grigore B, Peters J, Hyde C, Stein K. A comparison of two methods for expert elicitation in health technology assessments. BMC Med Res Methodol. 2016;16:85.","journal-title":"BMC Med Res Methodol"},{"key":"823_CR4","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40273-017-0525-1","volume":"35","author":"L Bojke","year":"2017","unstructured":"Bojke L, Grigore B, Jankovic D, Peters J, Soares M, Stein K. Informing reimbursement decisions using cost-effectiveness modelling: a guide to the process of generating elicited priors to capture model uncertainties. PharmacoEconomics. 2017;35:867\u201377.","journal-title":"PharmacoEconomics"},{"issue":"4","key":"823_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0272989X16670604","volume":"37","author":"Patricia Guyot","year":"2016","unstructured":"Guyot P, Ades AE, Beasley M, Lueza B, Pignon J-P, Welton NJ. Extrapolation of survival curves from Cancer trials using external information. Med Decis Mak. 2017;37(4):353\u201366.","journal-title":"Medical Decision Making"},{"key":"823_CR6","volume-title":"SEER Cancer Statistics Review, 1975-2014","author":"N Howlader","year":"2017","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, et al. SEER Cancer Statistics Review, 1975-2014. Bethesda: National Cancer Institute; 2017."},{"issue":"3","key":"823_CR7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1365-2141.2003.04584.x","volume":"123","author":"JM Chessells","year":"2003","unstructured":"Chessells JM, Veys P, Kempski H, Henley P, Leiper A, Webb D, Hann IM. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;123(3):396\u2013405.","journal-title":"Br J Haematol"},{"issue":"9","key":"823_CR8","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1200\/JCO.2007.12.2820","volume":"26","author":"C Oudot","year":"2008","unstructured":"Oudot C, Auclerc MF, Levy V, Porcher R, Piguet C, Perel Y, Gandemer V, Debre M, Vermylen C, Pautard B, et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol. 2008;26(9):1496\u2013503.","journal-title":"J Clin Oncol"},{"issue":"5","key":"823_CR9","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1097\/MPH.0b013e318290c3d6","volume":"35","author":"B Reismuller","year":"2013","unstructured":"Reismuller B, Peters C, Dworzak MN, Potschger U, Urban C, Meister B, Schmitt K, Dieckmann K, Gadner H, Attarbaschi A, et al. Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Munster) study group. J Pediatr Hematol Oncol. 2013;35(5):e200\u20134.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"16","key":"823_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"key":"823_CR11","volume-title":"Exploring the assessment and appraisal of regenerative medicines and cell therapy products","author":"R Hettle","year":"2016","unstructured":"Hettle R, Corbett M, Hinde S, Hodgson R, Jones-Diette J, Woolacott N, Palmer S. In: York CCUo, editor. Exploring the assessment and appraisal of regenerative medicines and cell therapy products. Heslington, York: CRD and CHE Technology Assessment Group, University of York; 2016."},{"key":"823_CR12","doi-asserted-by":"crossref","unstructured":"Grupp SA, Laetsch TW, Buechner J, Bittencourt H, Maude SL, Verneris MR, Myers GD, Boyer MW, Rives S, De Moerloose B, et al. Analysis of a global registration trial of the efficacy and safety of CTL-19 in pediatric and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL). Blood-J Hematol. 2016:128(22). \n                    https:\/\/biblio.ugent.be\/publication\/8525747\n                    \n                  .","DOI":"10.1182\/blood.V128.22.221.221"},{"key":"823_CR13","unstructured":"SHELF: the Sheffield Elicitation Framework (version 3.0). School of Mathematics and Statistics, University of Sheffield, UK [\n                    http:\/\/tonyohagan.co.uk\/shelf\n                    \n                  ]. Accessed 1 Apr 2017."},{"key":"823_CR14","doi-asserted-by":"crossref","unstructured":"O'Hagan A, Buck C, Daneshkhah A, Eiser J, Garthwaite P, Jenkinson D, Oakley J, Rakow T. Uncertain judgements: eliciting experts\u2019 probabilities. Statistics in Practice. Chichester: Wiley; 2006.","DOI":"10.1002\/0470033312"},{"issue":"4","key":"823_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jclinepi.2009.06.003","volume":"63","author":"SR Johnson","year":"2010","unstructured":"Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Feldman BM. Methods to elicit beliefs for Bayesian priors: a systematic review. J Clin Epidemiol. 2010;63(4):355\u201369.","journal-title":"J Clin Epidemiol"},{"key":"823_CR16","doi-asserted-by":"crossref","unstructured":"Maude SL, Pulsipher MA, Boyer MW, Grupp SA, Davies SM, Phillips CL, Verneris MR, August KJ, Schlis K, Driscoll TA, et al. Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed\/refractory acute lymphoblastic leukemia: results of an interim analysis. Blood-J Hematol. 2016;128:2801.","DOI":"10.1182\/blood.V128.22.2801.2801"},{"key":"823_CR17","doi-asserted-by":"crossref","unstructured":"Grupp SA, Maude SL, Shaw PA, Aplenc R, Barrett DM, Callahan C, Lacey SF, Levine BL, Melenhorst JJ, Motley L, et al. Durable remissions in children with relapsed\/refractory ALL treated with T-cells engineered with a CD19-targeted chimeric antigen receptor (CLT019). Blood-J Hematol. 2015;126:681.","DOI":"10.1182\/blood.V126.23.681.681"},{"issue":"3\u20134","key":"823_CR18","first-page":"258","volume":"1","author":"MJNM Ouwens","year":"2011","unstructured":"Ouwens MJNM, Philips Z, Jansen JP. Network meta-analysis of parametric survival curves. Res Synth Methods. 2011;1(3\u20134):258\u201371.","journal-title":"Res Synth Methods"},{"key":"823_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2288-11-61","volume":"11","author":"JP Jansen","year":"2011","unstructured":"Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol. 2011;11:61.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"823_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-12-152","volume":"12","author":"JP Jansen","year":"2012","unstructured":"Jansen JP, Cope S. Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. BMC Med Res Methodol. 2012;12(1):152.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"823_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/A:1018598421607","volume":"7","author":"AP Dempster","year":"1997","unstructured":"Dempster AP. The direct use of likelihood for significance testing. Stat Comput. 1997;7(4):247\u201352.","journal-title":"Stat Comput"},{"issue":"4","key":"823_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","volume":"64","author":"D Spiegelhalter","year":"2002","unstructured":"Spiegelhalter D, Best N, Carlin B, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Series B Stat Methodol. 2002;64(4):583\u2013639.","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"823_CR23","volume-title":"60th American Society of Hematology Annual Meeting: December 1\u20134 2018; San Diego, California","author":"SA Grupp","year":"2018","unstructured":"Grupp SA, Maude SL, Rives S, Baruchel A, Boyer MW, Bittencourt H, Bader P, B\u00fcchner J, Laetsch TW, Stefanski H, et al. Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia. In: 60th American Society of Hematology Annual Meeting: December 1\u20134 2018; San Diego, California; 2018. Abstract 895."},{"issue":"12","key":"823_CR24","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","volume":"24","author":"S Jeha","year":"2006","unstructured":"Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006;24(12):1917\u201323.","journal-title":"J Clin Oncol"},{"issue":"36","key":"823_CR25","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, et al. Phase I\/phase II study of Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381\u20139.","journal-title":"J Clin Oncol"},{"issue":"9","key":"823_CR26","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/jama.298.9.1010","volume":"298","author":"DM Windish","year":"2007","unstructured":"Windish DM, Huot SJ, Green ML. Medicine residents\u2019 understanding of the biostatistics and results in the medical literature. JAMA. 2007;298(9):1010\u201322.","journal-title":"JAMA"},{"issue":"4","key":"823_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00423-003-0410-6","volume":"388","author":"E Bollschweiler","year":"2003","unstructured":"Bollschweiler E. Benefits and limitations of Kaplan-Meier calculations of survival chance in cancer surgery. Langenbeck's Arch Surg. 2003;388(4):239\u201344.","journal-title":"Langenbeck's Arch Surg"},{"issue":"9318","key":"823_CR28","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","volume":"359","author":"SJ Pocock","year":"2002","unstructured":"Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359(9318):1686\u20139.","journal-title":"Lancet"},{"issue":"4","key":"823_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/1740774515586176","volume":"12","author":"RA Betensky","year":"2015","unstructured":"Betensky RA. Measures of follow-up in time-to-event studies: why provide them and what should they be? Clin Trials. 2015;12(4):403\u20138.","journal-title":"Clin Trials"},{"issue":"9","key":"823_CR30","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1056\/NEJMoa1510795","volume":"374","author":"G Armstrong","year":"2015","unstructured":"Armstrong G, Chen Y, Yasui Y, Leisenring W, Gibson TM, Mertens A, Stovall M, Oeffinger KC, Bhatia S. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2015;374(9):833\u201342.","journal-title":"N Engl J Med"},{"issue":"15","key":"823_CR31","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/sim.1203","volume":"21","author":"P Royston","year":"2002","unstructured":"Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175\u201397.","journal-title":"Stat Med"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-019-0823-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12874-019-0823-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-019-0823-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T23:18:42Z","timestamp":1598915922000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-019-0823-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1186\/s12874-019-0823-8","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,2]]},"assertion":[{"value":"12 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by Chesapeake Institutional Review Board (CIRB). Consent to participate was declared in written form.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SC, DA, and JJ are employees of Precision Xtract acting as consultants for Novartis Pharmaceutical Corporation; JZ is an employee of Novartis Pharmaceuticals; KB is a consultant for Precision Xtract and Novartis Pharmaceuticals Corporation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}